Zoetis Inc. $ZTS Holdings Increased by Privium Fund Management B.V.

Privium Fund Management B.V. raised its position in Zoetis Inc. (NYSE:ZTS) by 36.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 23,643 shares of the company’s stock after purchasing an additional 6,321 shares during the period. Privium Fund Management B.V.’s holdings in Zoetis were worth $1,651,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Alps Advisors Inc. grew its position in Zoetis by 60.8% during the third quarter. Alps Advisors Inc. now owns 47,850 shares of the company’s stock worth $3,341,000 after buying an additional 18,094 shares in the last quarter. Ashton Thomas Private Wealth LLC raised its holdings in shares of Zoetis by 16.0% in the 3rd quarter. Ashton Thomas Private Wealth LLC now owns 5,898 shares of the company’s stock valued at $412,000 after acquiring an additional 812 shares in the last quarter. International Assets Investment Management LLC raised its holdings in shares of Zoetis by 21.4% in the 3rd quarter. International Assets Investment Management LLC now owns 7,963 shares of the company’s stock valued at $550,000 after acquiring an additional 1,402 shares in the last quarter. Heritage Family Offices LLP purchased a new stake in shares of Zoetis in the 3rd quarter valued at about $50,000. Finally, Calamos Advisors LLC boosted its position in shares of Zoetis by 2.1% during the 3rd quarter. Calamos Advisors LLC now owns 116,633 shares of the company’s stock valued at $8,144,000 after acquiring an additional 2,360 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ZTS. TD Cowen cut their price objective on Zoetis from $104.00 to $94.00 and set a “buy” rating for the company in a report on Tuesday, August 25th. The Goldman Sachs Group began coverage on shares of Zoetis in a research report on Friday, October 16th. They issued a “neutral” rating and a $74.00 price objective on the stock. Cantor Fitzgerald set a $94.00 target price on shares of Zoetis in a research note on Tuesday, August 25th. Weiss Ratings raised shares of Zoetis from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, October 29th. Finally, William Blair cut shares of Zoetis from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 6th. Eight investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $101.25.

Zoetis Price Performance

Shares of ZTS traded down $2.61 during midday trading on Friday, reaching $79.50. The stock had a trading volume of 6,023,502 shares, compared to its average volume of 3,857,472. The company’s 50-day moving average is $75.68 and its 200 day moving average is $92.60. Zoetis Inc. has a 12-month low of $68.77 and a 12-month high of $132.49. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The company has a market capitalization of $32.85 billion, a price-to-earnings ratio of 13.52, a price-to-earnings-growth ratio of 1.23 and a beta of 0.67.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, November 5th. The company reported $1.75 earnings per share for the quarter, beating analysts’ consensus estimates of $1.51 by $0.24. The company had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%. Zoetis’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same period last year, the firm posted $1.70 EPS. On average, equities analysts predict that Zoetis Inc. will post 6.15 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Shareholders of record on Friday, October 30th will be given a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Friday, October 30th. Zoetis’s dividend payout ratio (DPR) is presently 34.93%.

More Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Adjusted EPS of $1.75 topped the $1.51 consensus, while revenue of $2.39 billion exceeded expectations of $2.30 billion. Zoetis also raised its full-year 2026 profit outlook. Zoetis Lifts Annual Outlook While Braces For Cautious Pet Economy
• Positive Sentiment: Livestock revenue grew 7% to $797 million, helping offset softness in companion-animal products. Jefferies also raised its price target to $85 from $83. Zoetis: 3 Key Takeaways for Long-Term Investors
• Negative Sentiment: Investors appear focused on ongoing pressure in the pet-health business: owners are cutting back on veterinary visits, and Zoetis is taking a cautious view of 2027. Competitive pressures and margin headwinds also weigh on the outlook. Zoetis plans cautiously for 2027 as pet owners cut back on vet visits, shares fall ZTS Q3 2026 deep dive: Competitive pressures and margin headwinds weigh on outlook
• Negative Sentiment: Despite beating estimates, quarterly revenue declined 1.3% year over year, reinforcing concerns that strength in livestock may not fully offset weaker companion-animal demand. Zoetis reports third-quarter results

About Zoetis

Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish.

The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.

Zoetis originated as Pfizer’s animal health business and became an independent public company in 2013.